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Introduction
Approximately 1.25 million persons in the
United States are chronically infected with
hepatitis B virus (HBV).1,2 An estimated 2% of
inmates in the U.S. have chronic HBV infec-
tion, five times the prevalence found in non-
incarcerated populations.3 Almost one third of
new HBV cases in the U.S. each year occur
among inmates or those who have been incar-
cerated.4 Although most HBV-infected inmates
acquired the infection prior to incarceration,
transmission of HBV has been well document-
ed within jails and prisons.5 This article will
review basic concepts of HBV transmission,
prevention, diagnosis, and treatment including
special considerations for the management of
hepatitis B in correctional settings.
Transmission
HBV is transmitted percutaneously and by
mucosal contact with the blood and body fluids
of chronically infected persons. In the United
States, most new cases of HBV are due to sex-
ual activity or injection drug use among unvac-
cinated adults. Less commonly, HBV is trans-
mitted through occupational and health care
associated mucosal or percutaneous exposure
to blood. Outbreaks of HBV have been linked
to contaminated equipment used for injections
and acupuncture.6, 7
Other recognized risks for HBV infection
include sharing a toothbrush, razor, or other
device that has come into contact with blood
from a person who is chronically infected with
HBV. Although skin or mucosal contact with
saliva from an HBV infected person has not
been linked to transmission of the virus, trans-
mission has occurred through a human bite.8
Natural history of HBV infection
Acute HBV infection is usually asymptomatic.
Those who do become clinically ill may experi-
ence an insidious onset of nausea, emesis,
abdominal discomfort, and anorexia.
Arthralgias, rash, and icterus may develop.
Primary infection is generally self limited, does
not lead to chronic viremia, and results in long
term immunity to re-infection. The likelihood
that chronic HBV will develop depends upon
the age at acquisition and the immune status of
the person who becomes infected.
Approximately 5% of HIV negative adolescents
and adults who become infected with HBV will
develop chronic infection, and 15-25% of those
who are chronically infected will develop cir-
rhosis, liver cancer, or liver failure due to
HBV.9,10 HIV/HBV co-infection is associated
with decreased clearance of hepatitis B sur-
face antigen and e antigen and increased HBV
viremia.11 Co-infection with HIV and HBV is
also associated with increased mortality as
compared to HIV monoinfection.12 Untreated
infants who acquire HBV perinatally have a
90% risk of chronic infection.13
Prevention
Routine immunization of infants, children, and
adolescents has contributed to a dramatic
decline in the incidence of new cases of HBV,
and continued effort to achieve universal child-
hood HBV vaccination is the best strategy for
HBV elimination. Currently, most acute cases
of HBV develop among unvaccinated adults.
Although most adults will accept HBV vaccina-
tion if it is offered to them, many at-risk adults
who are at highest risk for acute HBV infection
do not have ready access to free or low cost
vaccination services.14 Correctional facilities
can be ideal settings in which to reach adults
who are at-risk for HBV infection.
The Advisory Committee on Immunization
Practices (ACIP) recommends that HBV vacci-
nation be provided to all non-immune inmates
of correctional facilities. Routine vaccination
can be facilitated through the use of standing
orders for screening and immunization.15 HBV
vaccination consists of 3 intramuscular doses
in the deltoid muscle administered by one of
the following schedules: 0, 1, and 6 months; 0,
1, and 4 months; 0, 2, and 4 months, or 0, 1, 2,
and 12 months. A combined hepatitis A virus
(HAV) and HBV vaccine (Twinrix) is also avail-
able for adults who are non-immune to both
viruses. Twinrix can be administered at either
0, 1, and 6 months; or an accelerated schedule
of 0, 7, and 21-30 days, followed by a dose at
12 months. The latter schedule is particularly
useful in jails and other short-stay situations.
(See Table 1 for additional dosing informa-
tion).
The percentage of those who will develop a
protective level of HBV antibodies is
decreased in hemodialysis patients, HIV infect-
ed persons, men, those > 50 years old, and
smokers.16 Using a double dose of vaccine
has been shown to improve the response rate
to immunization in dialysis patients and those
who are HIV infected.17
In general, it is not necessary to test for immu-
nity following HBV vaccine. Testing should be
considered for those who will be at high risk for
ongoing exposure to blood or body fluids.
Those who failed to develop a protective level
of HBsAb should receive another course of
three doses of vaccine. Revaccination leads to
protective antibody levels in 50-100% of recip-
ients.18 Persons with chronic HBV should not
donate organs, blood, or semen.
Post Exposure Prophylaxis (PEP) for HBV
Pregnant women should be screened for HBV
so that prophylaxis can be given to the new-
borns of those with chronic HBV infection.
Administration of one dose of hepatitis B
immune globulin and initiating the three dose
HBV vaccination series within 24 hours after
birth is 85%-95% effective in preventing both
HBV infection and the chronic carrier state.13
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Dear Correctional Colleagues,
This week, the Pew Center on the States announced that an all-time high of more than one in 100
adult Americans are currently in jail or prison. In addition, the Center reported that more than $49
billion was spent on corrections last year, more than four times as much as twenty years ago. The
U.S. continues to lead all other countries in both the number and percentage of incarcerated cit-
izens.
Those of us who work in correctional public health certainly have little impact upon how many indi-
viduals this country chooses to incarcerate. We can, however, make an enormous difference in
the health of this nation by ensuring that inmates who are entrusted to our care benefit from our
best efforts at education, prevention, diagnosis, and treatment.
One area in which we can make a significant impact is chronic viral hepatitis. Hepatitis B virus
(HBV) immunization efforts targeting infants, children, and adolescents have achieved significant
success in the U.S. over the past two decades. As a result, non-immune adults now account for
the overwhelming majority of new HBV infections in this country. In most jails and prisons the
prevalence of HBV is markedly higher than that seen in the general U.S. population, and nearly
30% of persons with acute HBV have been incarcerated. Approximately 5% of adults who
become infected with HBV will develop chronic hepatitis. Persons with chronic viral hepatitis are
at risk for developing cirrhosis, end stage liver disease, and hepatocellular carcinoma.
Inmates continue to engage in behaviors that place them at risk for viral hepatitis both while incar-
cerated and after being released to the community. As a result, non-immune inmates comprise
a group who would potentially benefit from hepatitis prevention initiatives. It has become increas-
ingly clear that any effective comprehensive national strategy for the prevention, early diagnosis,
and treatment of viral hepatitis must include jails and prisons.
The Advisory Committee on Immunization Practices (ACIP) has called for routine vaccination of
all inmates who are not known to be immune regardless of their length of stay. Immunization of
non-immune adults, diagnosis and treatment of those who are chronically infected, substance
abuse treatment, and harm reduction education in the correctional setting can benefit our patients
and the free community by reducing transmission and by decreasing costs associated with chron-
ic viral hepatitis.
This month, Dr. Jennifer Cocohoba presents a comprehensive update regarding HBV. Dr.
Cocohoba addresses the ongoing evolution of HBV treatment, including the particular challenges
of treating those who are co-infected with HIV. Morris Jackson reviews some of the most useful
information from last month’s Conference on Retroviruses and Opportunistic Infections (CROI),
and the IDCR News and Reviews provides additional data from CROI 2008.
As always, we at IDCR thank you for your continued readership. We also encourage you to com-
municate with us regarding infectious diseases topics that you would like to see addressed in
future issues.
Joseph Bick, MD
Chief Deputy, Clinical Services
California Medical Facility
California Department of Corrections
LETTER FROM THE EDITOR
AN APPROACH TO HEPATITIS B VIRUS IN THE CORRECTIONAL SETTING
HBV PEP should be initiated for any non-
immune person who has occupational percuta-
neous or mucosal exposure to blood from a
chronically infected individual.13,19
(See Table 2)
Screening and diagnosis
The American Association for the Study of
Liver Diseases recommends HBV screening
for all inmates of correctional facilities.20 If
screening is conducted solely to identify those
who are unlikely to benefit from immunization,
testing for anti-HBc (HBcAb) and anti-HBsAg
(HBsAb) will identify those who have previous-
ly been infected or immunized. If the goal is to
identify both those who are immune and those
who have chronic HBV, it may be more useful
to obtain both HBsAg and anti-HBsAg
(HBsAb). Table 3 describes the interpretation
of HBV serologic markers.
Vaccinating those who are already immune to
HBV because of prior immunization or infec-
tion does not cause adverse effects. Whether
or not screening should be conducted prior to
vaccination depends upon the baseline preva-
lence of immunity and chronic HBV infection in
the population being immunized. In a study
conducted in the Texas Department of
Corrections, the cost of prevaccination testing
was equivalent to that of vaccination without
testing when the underlying HBV prevalence
reached 25%.21
Diagnosis of chronic HBV infection
Chronic HBV infection should be considered in
those who have persistent elevations in liver
transaminases. The diagnosis can be con-
firmed by the presence of hepatitis B surface
antigen that persists for greater than 6 months.
Occasionally, the only HBV serologic marker
that is present is anti-HBc. Isolated anti-HBc
can be a false positive, can be found in those
who have recovered from HBV infection but
have waning levels of HBsAb, who are chroni-
cally infected and have low levels of HBsAg.
The initial evaluation of a patient who has
chronic HBV should include a complete history
and physical examination. Blood testing
should include a complete blood count with
platelets, transaminases, albumin, prothrom-
bin time, and serologies for hepatitis A, C,
delta, and HIV. Hepatitis B specific laboratory
tests include hepatitis B surface antigen, e
antigen, anti-HBe, and hepatitis B viral DNA. A
serum alpha fetoprotein and ultrasound or CT
should be obtained every 6-12 months to
screen for hepatocellular carcinoma. Liver
biopsy is not routinely necessary in the diag-
nosis and management of chronic HBV.20
Treatment of HBV
Goals of therapy
The goals of HBV treatment are to suppress
viral replication, seroconvert from HBsAg to
HBsAb and HBeAg to HBeAb, and prevent
long-term liver damage that can result in cir-
rhosis, liver failure, and hepatocellular carcino-
ma. Treatment is generally recommended for
chronically infected patients who are
HBeAg(+) with ALT levels persistently greater
than 2 times upper limit of normal, and for
patients who are HBeAg(-) with HBV DNA
greater than 20,000 IU/mL and ALT levels per-
sistently greater than 2 times upper limit of nor-
mal.20 Treatment should be considered for
patients who are HBeAg(+) with ALT levels 1-
2 times the upper limit of normal and those
who are HBeAg(-) with HBV DNA levels
between 2,000 and 20,000 IU/mL and ALT 1-2
times upper limit of normal.20
Available treatments (See HBV 101)
Interferons
Interferon alfa was the first FDA approved
agent for the treatment of hepatitis B. In clini-
cal trials, therapy with interferon resulted in 32-
79% of participants clearing HBV-DNA, but
only 10-15% demonstrated seroreversion of
the HBsAg.22-26 Predictors of a favorable
response to interferon therapy include lower
baseline levels of HBV DNA and high amino-
transferase levels. Due to the inconvenience of
multiple weekly subcutaneous injections, treat-
ment with interferon has largely been replaced
by once weekly pegylated interferon and oral
nucleoside/nucleotide analogs.jjjjjjjjjjjjjjjjjjjjjjjj
Seroconversion of HBeAg and HBsAg is more
frequent with peg-interferon compared to
lamivudine over shorter study periods.
However, treatment with lamivudine is not usu-
ally given short term.27,28
Nucleoside and Nucleotide analogs
Nucleoside and nucleotide analogs interfere
with the ability of the HBV polymerase to syn-
thesize viral DNA. With all agents in this class,
there is a risk of acute HBV exacerbation upon
abrupt cessation of therapy. In clinical trials,
most cases were marked by asymptomatic
increases in liver transaminases and increases
in HBV viremia, although a few cases were
fatal. Care must be taken to taper, substitute,
or monitor closely when these HBV therapies
are discontinued.
Lamivudine (Epivir HB)
Lamivudine was the first oral medication
approved by the FDA for the treatment of HBV,
and is generally well-tolerated A study of 651
Chinese patients randomly assigned to receive
lamivudine or placebo was terminated after a
median of 32.4 months due to a difference in
hepatic disease progression and death
between the treatment and placebo arms
(7.8% versus 17.7%, HR for progression
=0.45, p =0.001).29 In an Italian study, 93.9%
of HBeAg(-) patients achieved a HBV virologi-
cal response after approximately 22 months
treatment. At the 4-year follow up, the propor-
tion with a virologic response had decreased to
39%. In the multivariable analyses, viral break-
through increased the risk for hepatocellular
carcinoma and end stage liver disease. (p<
0.001).30 In another double-blind placebo con-
trolled clinical trial of 139 HBeAg(-) patients, a
median 3.21 log copies/mL reduction in HBV
DNA was achieved in the lamivudine arm com-
pared to only 0.47 log copies/mL (p < 0.001)
for placebo. After 244 months, more lamivu-
dine patients (56% vs. 11%, p < 0.001) had
achieved a complete response to therapy.31 In
a smaller study of 34 HBeAg(+) patients treat-
ed with lamivudine for one year, 70.6% at one
year, 64.7% at 2 years, and 55.8% at 3 years
had undetectable HBV DNA and normalization
of transaminase levels.32 Another small study
of 20 Japanese patients treated with lamivu-
dine for more than one year, and followed for a
median of 8.5 years, found a 30% increase in
HBeAg clearance and a 55% increase in the
proportion of patients with undetectable HBV
DNA at the end of the study.33
The efficacy of lamivudine does not appear to
be affected by renal transplant or hemodialy-
sis.34 Resistance to lamivudine is conferred by
a mutation in the YMDD region of the HBV
polymerase. This mutation is common and
occurs in 24%, 56%, and 75% of patients after
one, two, and three years respectively. A small
study in 30 patients suggests that early detec-
tion of the YMDD mutation may be useful for
predicting virologic breakthrough at 24 months
(p=0.003).35 Clinical benefits to lamivudine
therapy may be decreased in patients who
develop the YMDD mutation. In a study of 74
patients who continued on lamivudine therapy
for 3 years, 15% versus 64% demonstrated
histologic improvement at 3 years, 54% versus
32% remained unchanged, and 31% versus
5% worsened histologically for those with the
YMDD versus wild-type variant.36
Adefovir (Hepsera)
Adefovir was initially evaluated for its anti-HIV
activity before dose-limiting renal toxicity halt-
ed further study. It was later discovered that
adefovir completely inhibits HBV viral replica-
tion at lower, less nephrotoxic doses. One
large clinical trial of adefovir in 185 HBeAg(-)
patients randomly assigned participants to
receive treatment or placebo for 48 weeks.37
At 48 weeks, participants were again random-
ly assigned to receive adefovir versus placebo
for an additional 48 weeks of therapy. Median
HBV DNA reduction among those receiving
adefovir was 3.63 log copies/mL, and 79% of
participants had an undetectable HBV DNA at
144 weeks.
Potential adefovir resistance mutations were
identified in 5.9% of patients after 144 weeks
of therapy. 125 subjects enrolled in a continu-
ation arm of this study to 240 weeks demon-
strated a durable response. In 67% of partici-
pants HBV DNA remained < 1000 copies/mL,
ALT levels remained normalized in 69%, and
73% had decreased fibrosis.38 A randomized
clinical trial of adefovir versus placebo in 515
HBeAg(+) patients found 53% versus 25% his-
tologic improvement (p < 0.001), 21% versus
0% undetectable HBV-DNA (p<0.001), and
48% versus 16% ALT normalization (p<0.001)
at 48 weeks.39 In addition, HBeAg seroconver-
sion was achieved in 12% versus 6% of
patients (p=0.049). A randomized double-blind
placebo-controlled clinical trial of adefovir in
480 Chinese subjects found a median reduc-
tion of 4.5 log copies/mL, 28% of subjects
undetectable HBV DNA, and 79% of subjects
with normalization of ALT at 52 weeks.40
Adefovir is active versus lamivudine-resistant
HBV and may be useful for salvage therapy. A
number of studies have looked at the combi-
nation of lamivudine and adefovir for the treat-
ment of lamivudine resistant HBV, however the
clinical and serologic benefits of combination
therapy are not yet well-established.41-47
There is insufficient data to recommend com-
bination therapy in treatment naive individuals.
Adefovir is effective in patients with renal insuf-
ficiency, those undergoing hemodialysis, and
those who have had a kidney transplant.48, 49
Entecavir (Baraclude)
Entecavir is a potent guanosine nucleoside
analogue for the treatment of HBV. In a phase
3 double blind randomized study of entecavir
versus lamivudine in 648 HBeAg(-) patients, a
higher proportion of entecavir treated subjects
demonstrated histologic improvement (70%
versus 61%, p=0.001), undetectable HBV DNA
(90% vs 72%, p < 0.001) and normalization of
ALT levels (78% vs. 71%, p=0.045) at 48
weeks.50 A phase 3 trial of entecavir versus
lamivudine in 715 HBeAg(+) patients also
found a higher proportion of histologic
improvement (72% vs 62%, p =0.009), unde-
tectable HBV DNA (67% vs. 36%, p < 0.001)
and normalization of ALT (68% vs. 60%, p
=0.02) for entecavir treated subjects.51 These
outcomes appear to be similar after 2 years of
therapy: in a study of 709 HBeAg(+) patients
80% vs 39% (p< 0.0001) achieved unde-
tectable HBV DNA and 87% vs 79% ( p =
3
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40.0056) demonstrated normalization of ALT
levels at 96 weeks, though there was no differ-
ence in HBeAg seroconversion (31% vs.
25%).52 The incidence of resistance to ente-
cavir is thought to be low and develops via a
two-step process which requires lamivudine
resistance mutations to develop in combination
with further mutations. Therefore, although
entecavir appears to be effective in the treat-
ment of lamivudine-resistant HBV, it is not rec-
ommended to use them in combination.53-55
In comparison to adefovir, entecavir has been
shown to be superior for virological endpoints
in both HBeAg(-) and HBeAg(+) populations
and for ALT normalization and seroconversion
in HBeAg(+) individuals. Entecavir was also
superior to adefovir for histological endpoints
in HBeAg(+) persons, and comparable in
HbeAg(-) persons.56
Telbivudine (Tyzeka)
Telbivudine is the newest nucleoside analogue
approved for the treatment of hepatitis B. In a
1370 person, randomized, non-inferiority trial
of telbivudine 600mg versus lamivudine
100mg, telbivudine was non-inferior to lamivu-
dine for HBeAg(-) patients in achieving nor-
malization of ALT or a histologic response after
52 weeks of therapy.57 For HBeAg(+) patients,
a higher proportion achieved a histologic
response in the telbivudine arm (64.7% vs
56.3%, p =0.01) compared to lamivudine arm.
Telbivudine has also been compared to ade-
fovir in a 52-week open label study of 135
HBeAg(+) patients.58 Subjects received tel-
bivudine for 52 weeks, adefovir for 52 weeks,
or adefovir for 24 weeks, followed by telbivu-
dine for 28 weeks. At week 24, patients in the
telbivudine arm had a higher odds of having
undetectable HBV DNA compared to the other
arms pooled together (OR 4.46 1.86-10.72,
p=0.001). There do not appear to be significant
drug-drug interactions between telbivudine
and adefovir or lamivudine.59 Single dose
studies have suggested that telbivudine can be
used across varying degrees of hepatic impair-
ment and that its pharmacokinetics are unal-
tered if co-administered with food.60,61
Telbivudine also selects for mutations in the
YMDD region of HBV polymerase though at a
slower rate than lamivudine (4.4% after 1 year,
21.6% after 2 years). Adefovir may also be
useful for patients who have developed resis-
tance to telbivudine.
Combination Interferon/nucleoside therapy
In a randomized, controlled, open-label trial of
100 HBeAg-positive patients, sustained sero-
conversion and HBV DNA < 500,000 copies
was achieved in a higher proportion of patients
treated with peg-interferon plus lamivudine
(36%) versus lamivudine alone (14%).27 In a
study of 814 HBeAg-positive patients more
subjects assigned to peg-interferon plus
lamivuine or peg-interferon alone achieved
HBeAg seroconversion (32% vs. 27% vs. 19
%; p = 0.02 and p < 0.001 respectively) com-
pared to treatment with lamivudine alone after
24 weeks. Sixteen patients in the peg-interfer-
on groups had HBSAg seroconversion com-
pared to zero in the lamivudine only group.62 A
study in HBeAg-negative patients treated for
48 weeks found HBV DNA suppression was
achieved in a higher proportion of patients on
pegylated interferon monotherapy (19%) or
combination lamivudine therapy (20%) as
compared to lamivudine alone (7%) at 24
weeks post treatment.28 Normalization of ALT
was also higher in the peg-interferon groups
(59% and 60%) versus lamivudine alone
(44%).
Selection of therapy
Selection of therapy should be based on a vari-
ety of factors including efficacy, toxicity, avail-
ability, duration, route of administration, patient
preference, provider preference, co-presence
of HIV infection, and potential for resistance.
For HBeAg(-) patients that require more than
one year of therapy, lamivudine and telbivu-
dine may be less optimal choices due to the
potential for resistance after long treatment.
For patients who are unable to be monitored
closely, interferon therapy may not be optimal
due to the many side effects and numerous
laboratory studies required. For HIV positive
patients, antiretroviral therapies may already
provide suppression of HBV and additional
therapy may not be required.
Treatment of HBV/HIV co-infection
Special considerations should be made to opti-
mize therapy for patients who are co-infected
with HIV and HBV. For co-infected patients
who meet clinical indications for treatment of
both HIV and HBV, the antiretroviral regimen
should include agents that are active against
both viruses. Tenofovir and either lamivudine
or emtricitabine in combination with a protease
inhibitor or a non-nucleoside reverse transcrip-
tase inhibitor is a good initial choice. For co-
infected patients who do not meet clinical indi-
cations for treatment of HIV but require thera-
py for hepatitis B, interferon or adefovir can be
utilized. Less is known about telbivudine, but it
is thought to have no anti-HIV activity and
could potentially be used. Lamivudine, emtric-
itabine, tenofovir and entecavir should not be
given as monotherapy to an HIV/HBVinfected
patient because HIV resistance mutations may
develop. Acute hepatitis flare-ups can occur
when HBV replication increases, such as when
the antiretroviral regimen is changed and
drugs active against HBV are discontinued.
Therefore, the selection of HIV salvage regi-
mens must take into account the HBV status of
the patient. Flares can also occur when HBV
develops resistance, or when antiretroviral
therapy leads to an immune reconstitution
inflammatory response (IRIS).
Monitoring and follow-up
Treatment success can be determined by
monitoring for seroconversion of HBeAg in
HBeAg(+) patients, appearance of anti-
HBeAg, normalization of aminotransferases,
viral suppression of HBV DNA, and histologic
improvement. For patients treated with inter-
feron, 16-24 weeks is ideal for HBeAg(+)
patients while 12 months of therapy might be
required for HBeAg(-) patients. Liver function
tests can be monitored every 3 months during
treatment and HBV DNA should be monitored
every 3-6 months. One year after treatment,
and every 3-6 months thereafter, patients
should be tested for the eAg and anti-HBe. If
seroconversion occurs, treatment should con-
tinue for at least 6 months after appearance of
anti-HBeAg, then stopped. Sustained virologic
suppression can be achieved in a significant
number of HBeAg(+) patients who serocon-
vert. If seroconversion does not occur, treat-
ment may be continued. If virologic break-
through is present, the treating clinician may
consider switching to another active agent.
For HBeAg(-) patients optimal treatment dura-
tion is less clear but is usually one year or
longer. Doses and common adverse effects for
all anti-hepatitis B agents are presented in
HBV 101.
Conclusions
Jails and prisons provide unique opportunities
and challenges for the prevention, diagnosis,
and treatment of chronic viral hepatitis.
Improving hepatitis B management programs
within correctional institutions has the potential
to benefit the individual, the correctional popu-
lation, and the larger public health. The optimal
treatment of chronic HBV continues to evolve,
especially in the HIV co-infected person.
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SPOTLIGHT: THE 2008 CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC
INFECTIONS (CROI): A COMMUNITY PERSPECTIVE
IDCR invited Morris Jackson to report back from CROI on the issues
that he found to be most significant for our readership. Mr. Jackson
is the Treatment Education Coordinator with the Los Angeles based
Center for Health Justice. He also serves as a community member on
the DHHS Panel on Antiretroviral Guidelines for Adults and
Adolescents, and is a member of the AIDS Treatment Activist
Coalition’s (ATAC) Board of Directors and ATAC’s Drug Development
Committee.
I was again fortunate this year to be a CROI Community Educator Program
Awardee recipient. As a PLWA/HIV and an advocate for the health care
needs of the incarcerated, I had dual filters through which to interpret the
data/findings presented and left with renewed vigor to make the information
gleaned relevant and empowering to those who may not have been able to
attend this meeting.
CROI is enormous in scope and it is impossible for one person to attend
every session. The following is a brief synopsis of what I thought was some
of the most interesting and ‘correctionally’ relevant data presented.
Raltegravir (Isentress, MK-0528): This agent is the first integrase
inhibitor to receive FDA approval. Integrase inhibitors are a novel class of
antiretrovirals. After the reverse transcription of HIV viral RNA into DNA is
complete, integration of the HIV DNA into the host cell’s DNA occurs.
Integrase inhibitors work by blocking this process. Raltegravir, combined
with optimized background therapy (OBT), was shown to offer durable effi-
cacy and safety in patients with multiple-drug-resistant HIV and a history of
treatment failure.1,2 Many incarcerated HIV patients have exhausted treat-
ment options, and raltegravir offers an additional tool for creation of salvage
therapy for patients who have developed extensive resistance.
Etravirine (Intelence, TMC 125): Etravirine is the first non-nucleoside
reverse transcriptase inhibitor (NNRTI) to receive FDA approval in the last
10 years. In treatment-experienced patients with multi-drug resistance, a
regimen of etravirine plus OBT demonstrated greater viral load (VL) reduc-
tion and increase in CD4 counts compared to placebo plus OBT.3,4
Etravirine is approved for treatment-experienced patients who have HIV
that is resistant to multiple antiretroviral drugs. The FDA has not approved
etravirine for use in treatment naive patients.
Nevirapine: Once-daily dosing of 400mg of the NNRTI nevirapine
(Viramune, NVP) was shown to be as effective as 200mg twice-daily.
Further, investigators concluded that “[f]or patients with detectable HIV
RNA who have been exposed to other antiretroviral drugs, and commence
a regimen including NVP, NVP once-daily, is associated with better and, a
faster, virological suppression, as well as a stronger immune restoration
(as compared to twice daily).” 5 Once-daily NVP may help decrease costs
associated with medication administration in the correctional setting.
Lopinavir/ritonavir (Kaletra): Data was presented that demonstrated
comparable tolerability and efficacy between 4 tablets once-daily and two
tablets twice-daily of Kaletra (lopinavir /ritonavir).6 The January 29, 2008,
update of DHHS’s federal treatment guidelines suggests that twice-daily
Kaletra may be more suitable for those patients with high (> 100,000
copies/mL) pre-treatment viral loads.7
HIV diagnosis and perceived transmission risk factors: During the
symposium “Curbing the US Epidemic,” incarceration was cited as an
important HIV transmission risk factor no less than six times, specifically in
relation to the sexual network patterns and societal disparities of African-
American women.8 By extrapolation, this seemingly speaks to the need for
improved prison/jail prevention efforts. Perhaps eradicating behavioral risk
group (BRG) labeling in HIV testing is a beginning toward that end. For
example, many male inmates do not identify themselves as MSM, and
therefore do not perceive themselves at risk for contracting HIV and then
transmitting it to their post-release female sexual partners. In a blinded
serostudy of New York City jail entrants, most HIV infected inmates did not
report recognized HIV risk factors.9
In a study of 21,419 adult prisoners entering the North Carolina Department
of Corrections from January 2004 to May 2006, “associations between HIV
serostatus and conventional HIV risk behaviors, mental health, co-infection
status, and sociodemographic characteristics were estimated using logistic
regression.”10 In this study, “approximately 40% of prisoners were volun-
tarily tested for HIV, and nearly 3.4% ... were HIV+.” “Among men, HIV
infection was most strongly associated with men who have sex with men
(MSM) (OR 8.0), black race (OR 6.2), other non-white race (OR 7.4), and
age 35 to 44 years (OR 4.1). The strongest risk factor among women was
black race (OR 3.8).” The authors estimated that between 23% and 67% of
HIV cases remained undetected. This study provided additional evidence
that risk factor-based HIV testing in prison fails to diagnosis a significant
number of those who are HIV-infected.
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Exposure Unvaccinated§ Previously Vaccinated Person¶
HBsAg**-positive source
Percutaneous (e.g. bite or needlestick) Administer hepatitis B vaccine series and Administer hepatitis
or mucosal exposure to HbsAg-positive hepatitis B immune globulin (HBIG) B vaccine booster dose
blood or body fluid
Sex or needle-sharing contact of an Administer hepatitis B vaccine series and Administer hepatitis
HbsAg-positive person hepatitis B immune globulin (HBIG) B vaccine booster dose
Victim of sexual assault/abuse by a perpetrator Administer hepatitis B vaccine series and Administer hepatitis
who is HbsAg-positive hepatitis B immune globulin (HBIG) B vaccine booster dose
Source with unknown HbsAg status
Victim of sexual assault/abuse by a perpetrator
with unknown HbsAg status Administer hepatitis B vaccine series No treatment
Percutaneous (e.g. bite or needlestick) Administer hepatitis B vaccine series No treatment
Or mucosal exposure to potentially
Infectious blood or bodily fluids from a source
With unknown HbsAg status
Sex or needle-sharing contact of an Administer hepatitis B vaccine series No treatment
HbsAg-positive person
Table 2: Guidelines for Postexposure Prophylaxis* of Persons with Nonoccupational Exposures‡ to
Blood or Body Fluids that Contain Blood, by Exposure Type and Vaccination Status
* When indicated, immunoprophylaxis should be initiated as soon as possible, preferably within 24 hours. Studies are limited on the maximum interval after exposure during
which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures and 14 days for sexual exposures. The hepatitis B vac-
cine series should be completed.
‡ These guidelines apply to nonoccupational exposures. Guidelines for the management of occupational exposures have been published separately, and can also be used
for the management of nonoccupational exposures if feasible.
§ A person who is in the process of being vaccinated but has not completed the vaccine series should complete the vaccine series and receive treatment as indicated.
¶ A person who has written documentation of a complete hepatitis B vaccine series and who did not receive post vaccination testing.
** Hepatitis B surface antigen.
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Source: A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee
on Immunization Practices (ACIP) Part II: Immunization of Adults MMWR December 8, 2006 / 55(RR16); 1-25.
Single-antigen vaccine Combination Vaccine
Recombivax HB®* Engerix-B®† Twinrix®†§
Dose Vol. Dose Vol. Dose Vol.
Group (µg¶) (mL) (µg¶) (mL) (µg¶) (mL)
Adults (aged ≥ 20 years) 10 1.0 20 1.0 20 1.0
Hemodialysis patients and other 40** 1.0 40†† 2.0 NA§§ NA
immunocompromised person
≥ 20 years
Table 1: Recommended Doses of Currently Licensed Formulations of Adult Hepatitis B Vaccine, by
Group and Vaccine Type
Source: A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee
on Immunization Practices (ACIP) Part II: Immunization of Adults MMWR December 8, 2006 / 55(RR16); 1-25.
* Merck & Co., Inc., Whitehouse Station, New Jersey
† GlaxoSmithKline Biologicals, Rixensart, Belgium
§ Combined hepatitis A and hepatitis B vaccine, recommended for persons aged ≥ 18 years who are at increased risk for both hepatitis B and A virus infections
¶ Recombinant hepatitis B surface antigen protein dose
** Dialysis formulation administered on a 3 dose schedule at 0, 1, 2, and 6 months
†† Two 1.0-mL doses administered in 1 or 2 injections on a 4-dose schedule at 0, 1, 2, and 6 months
§§ Not applicable
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interferon alfa-2b
Intron A
3, 5, 10, 18, 25, 50 million IU
Or
peginterferon alfa-2a
Pegasys
180 mcg/mL
Laboratory Assesment Dose Common adverse effects Laboratory Assesment
HBeAg-positive patients:
5-6 million units SQ once-daily OR
9-10 million units SQ three times
weekly x 4-6months
HBeAg-negative patients:
5-6 million units SQ three times
weekly x 12 months
Peginterferon:
180 mcg SQ once weekly x 48
weeks
Anemia, granulocytopenia, throm-
bocytopenia, psychiatric distur-
bances (depression, suicide, psy-
chosis), CNS effects such as
seizures, ataxia, confusion, cardiac
arrythmias, cardiomyopathy,
myocardial infarction, hypotension,
thyroid disturbances, renal failure,
dermatologic disturbances, injection
site reactions
Should not be used in patients with
severe depression or unstable psy-
chiatric disorders, uncontrolled thy-
roid disease or diabetes, in
patients with ANC < 1.5 or
platelets < 75 or in pregnant
patients
Monitor CBC, platelets, liver func-
tion tests, TSH, blood glucose,
renal function every 4 weeks
lamivudine
Epivir-HBV
100mg tablets
HBV monoinfected: 100mg orally
once-daily
HBV/HIV co-infected: 300mg orally
once-daily, in combination with other
agents to make a HAART regimen
Headache, fatigue, nausea, myopa-
thy/myalgia, lactic acidosis, HBV
flare upon abrupt discontinuation
Dose adjust in renal insufficiency
adefovir
Hepsera
10mg tablets
10mg orally once-daily Weakness, headache, nausea,
abdominal pain, hematuria, renal
dysfunction, HBV flare upon abrupt
discontinuation.
Dose adjust in renal insufficiency
entecavir
Baraclude
0.5 and 1mg tablets
Treatment naive:
0.5mg orally once-daily
Lamivudine experienced:
1mg orally once-daily
Headache, fatigue, hyperglycemia,
elevated lipase and amylase,
hematuria, lactic acidosis, HBV
flare upon abrupt discontinuation.
Dose adjust in renal insufficiency
telbivudine
Tyzeka
600mg tablets
600mg orally once-daily Fatigue, malaise, headache,
abdominal pain, increased CPK,
dizziness, lactic acidosis, myopathy,
HBV flare upon abrupt discontinua-
tion.
Dose adjust in renal impairment.
Consider baseline and follow up
CPK.
FDA Approved Medications for Prevention and Treatment of Hepatitis B Virus
February/March 2008 Vol. 9, Issue 22 visit IDCR online at www.IDCRonline.org
Total IgM§
anti- anti- Anti-
HbsAg* HBc† HBc HBs¶ Interpretation
-** - - - Never infected
+††§§ - - - Early acute infection; transient (up to 18 days) after vaccination
+ + + - Acute infection
- + + - Acute resolving infection
- + - + Recovered from past infection and immune
+ + - - Chronic infection
- + - - False positive (i.e., susceptible); past infection; “low-level” chronic infection;
¶¶ passive transfer to infant born to HbsAg-positive mother
- - - + Immune if concentration is ≥ 10 MIU/ML,*** passive transfer after hepatitis B immune
globulin administration
Table 3: Typical Interpretation of Serologic Test Results for Hepatitis B Virus Infection
Serologic Marker
* Hepatitis B surface antigen
† Antibody to hepatitis B core antigen
§ Immunoglobulin M.
¶ Antibody to HbsAg
** Negative test result
†† Positive test result
§§ To ensure that and HBsAg-positive test result is not a false positive, samples with repetedly reactive HBsAg results should be tested with a licensed (and, if appropriate,
neutralizing confirmatory) test.
¶¶ Persons positive for only anti-HBc are unlikely to be infectious except under circumstances in which they are the source for direct percutaneous exposureof susceptible
recipients to large quantities of virus (e.g., blood transfusions, organ transplant).
*** Milli-International Uni
Source: A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee
on Immunization Practices (ACIP) Part II: Immunization of Adults MMWR December 8, 2006 / 55(RR16); 1-25.
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Resuming Therapy Doesn’t Reverse Progression Risk of Off-and-On
Therapy
Wafaa El-Sadr of the Harlem Hospital Center, New York presented addi-
tional data regarding the decision to halt the Strategies for Management
of Anti-Retroviral Therapy (SMART) study. SMART, which ended two
years ago, examined the impact of suspending antiretroviral therapy
(ART) during periods of high CD4 counts. SMART consisted of two arms:
one group continued ART throughout the study, while the other group dis-
continued ART when CD4 counts rose above 350/mm3 and resumed
ART when the CD4 count fell below 250/mm3. The study was ended
when it was determined that people in the interrupted ART group were at
1.8 times higher risk of death from any cause, as well as a 1.7 times high-
er risk of major cardiovascular, renal, or hepatic disease.
The interrupted group continued to experience worse health outcomes
even after the study’s termination in January 2006, at which time the
investigators had counseled patients to resume uninterrupted treatment.
Participants who had been assigned to the interrupted treatment group
had a 24% higher risk of heart, kidney, or liver disease, a 37% higher risk
of opportunistic disease or death, and a 41% higher risk of death than
those in the control group of uninterrupted treatment. Members of the
interrupted treatment group spent an average of 71% of the time on ther-
apy, substantially less than the 91% of time spent on treatment in the con-
trol group. When researchers compared only people who had spent more
than 85% of their time on ART, the risk of opportunistic infection or death
appeared equivalent between the two groups.
Three factors were postulated to explain the disparity in health outcomes
between the study’s two arms. Some members of the interrupted treat-
ment group did not resume ART therapy after the study’s completion, thus
limiting the effectiveness of treatment. Secondly, CD4 counts stayed
lower in members of the interrupted treatment group, even if they did
restart therapy. Finally, opportunistic diseases diagnosed before the
study’s completion may have had a long-term impact on the health of indi-
viduals. This study suggests that the impact of CD4-guided drug breaks
may be long-lasting.
Mascolini, Mark. Resuming Therapy Can’t Reverse Progression Risk
With Off-and-On Therapy. 15th Conference on Retroviruses and
Opportunistic Infections. February 3-6, 2008. Boston.
48-Week Results from BENCHMRK-2, a Phase III Study of
Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART)
with Triple-Class Resistant HIV-1
Results from an ongoing double-blind Phase III study have demonstrated
raltegravir’s effectiveness in suppressing HIV viral loads. The study found
that patients who took 400 milligrams of raltegravir twice daily in combi-
nation with optimized background therapy (OBT) had lower viral loads
than patients whose treatment regimens included OBT and a placebo.
The results were gathered after 48 weeks of treatment amongst patients
living with HIV-1 in North and South America.
The success of this study offers hope to treatment-experienced individu-
als living with antiretroviral-resistant HIV, as well as the treatment-naive.
Raltegravir, which acts as an HIV-1 integrase strand-transfer inhibitor,
can be taken in combination with NRTIs, NNRTIs, PIs, and efuvirtide in
order to combat multi-drug resistant strands of HIV. In addition, strains of
HIV that become resistant to raltegravir may still remain sensitive to other
types of antiretrovirals.
Levin, Jules. 48-Week Results from BENCHMRK-2, a Phase III Study of
Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with
Triple-Class Resistant HIV-1. 15th Conference on Retroviruses and
Opportunistic Infections. February 3-6, 2008. Boston.
Immediate Antiretrovirals During Acute OI Lower Death Risk: ACTG
A5164
A Stanford University research team headed by Andrew Zolopa present-
ed data from a randomized trial of 282 patients that evaluated whether or
not to complete treatment of AIDS-related opportunistic infections (OI)
before beginning ART in HIV-infected patients.
The study included individuals with acute OI including Pneumocystis
pneumonia, bacterial pneumonia, cryptococcosis, Mycobacterium avium
complex, or central nervous system toxoplasmosis. Participation was lim-
ited to patients who had never experienced antiretroviral failure and had
not taken ART in the past 8 weeks or for more than 31 days in the past 6
months. The participants were evenly split into two treatment arms. While
both groups received immediate treatment of their OI, one group also
received immediate treatment with ART. The other group deferred ART
until at least 28 days after enrollment in the study.
24.1% of those in the deferred group had a new AIDS diagnosis or had
died, compared to 14.2% in the immediate treatment group. As such, par-
ticipants who deferred antiretroviral treatment had twice the chance of
progression as participants who began treatment immediately.
Participants who received immediate treatment experienced a faster
increase in CD4 count, thus limiting their period of vulnerability to new OIs
or death. Differences in progression rates and death between the two
groups were mainly limited to the first 6 months of the study, as there was
little difference in the viral loads of the two groups by week 48. These find-
ings emphasize the importance of immediate ART for patients suffering
from acute AIDS-related OIs.
Mascolini, Mark. Immediate Antiretrovirals During Acute OI Lower Death
Risk: ACTG A5164. 15th Conference on Retroviruses and Opportunistic
Infections. February 3-6, 2008. Boston.
Sustained Virological Response to Interferon plus Ribavirin
Reduces Liver-related Complications and Mortality in HIV/HCV Co-
infected Patients
A recent analysis of the GESIDA 3603 Study Cohort provided new infor-
mation on the impact of sustained virological response (SVR) on
HIV/HCV coinfected patients. The study consisted of 711 patients who
began interferon-ribavirin treatment between January 2000, and
December 2005. Patients were seen every 6 months for 18 to 22 months,
and clinical outcomes such as mortality, liver-related complications, and
HIV progression were assessed. An estimated 31% of the study popula-
tion achieved SVR during the course of this study. The health outcomes
of this group were then compared to the remainder of the participants who
did not achieve SVR.
Among the 218 people who achieved a SVR, the death rate was only .9%.
This compared to a death rate of 6.9% among the 493 patients who did
not achieve SVR. Liver related complications affected 3.7% of the non-
SVR group and .5% of the SVR group. 2.2% of the non-SVR group had
liver transplants, compared to 0% of the SVR-achieving group. In total,
members of the non-SVR group had a 9 times greater risk of death, 20
times greater risk of liver decomposition, and 4 times greater risk of new
AIDS conditions.
Levin, Jules. Sustained Virological Response to Interferon plus Ribavirin
Reduces Liver-related Complications and Mortality in HIV/HCV-co-infect-
ed Patients. 15th Conference on Retroviruses and Opportunistic
Infections. February 3-6, 2008. Boston.
Compiled by Christine Devore, Duke University
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT - MEC #7256
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing
Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR. MEC is accredited by the ACCME
to provide continuing medical education for physicians.
Medical Education Collaborative designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. The target audience
for this educational program is physcians. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Statements of credit will be mailed within 6 to 8 weeks following the program.
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In order to receive credit, participants must score at least a 75% on the post test and submit it along with the credit
application and evaluation form to the address/fax number indicated. Statements of credit will be mailed within 6-8 weeks fol-
lowing the program.
Please print clearly as illegible applications will result in a delay.
Name: _________________________________________________ Profession: __________________________________
License #: ___________________________________ State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please check which credit you are requesting ___ ACCME or ___ Non Physicians
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
I certify that I participated in IDCR monograph February/March 2008 Issue
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________
Number of Hours (max. 1): ___________________
Signature: _________________________________________________
Please Submit Completed Application to:
Medical Education Collaborative
651 Corporate Circle, Suite 104, Golden CO 80401
Phone: 303-420-3252 FAX: 303-420-3259
For questions regarding the accreditation of this activity, please call
303-420-3252
Instructions:
• Applications for credit will be accepted until
March 26, 2009.
• Late applications will not be accepted.
• Please anticipate 6-8 weeks to recieve your certificate.
Objectives:
The leaner will be able to describe the recommended treatment, dosing, and monitoring options for the treatment and management of the
hepatitis B virus.
The learner will be able to explain the prevention, screening, and diagnosis measures for the hepatitis B virus.
The learner will be able to discuss the most significant studies presented at the 2008 Conference on Retroviruses and Opportunistic Infections
(CROI).
1. Which of the following is NOT a recommended schedule for hepatitis B
vaccination?
A. 0,1, and 6 months
B. 0, 1, and 4 months
C. 0, 1, and 5 months
D. 0, 1, 2, and 12 months
E. None of the above
2. The CDC recommends that an unvaccinated victim of sexual
assault/abuse by a perpetrator with unknown HbsAg status does NOT
need to be treated with hepatitis B postexposure prophylaxis.
TRUE or FALSE
3. Which of the following is a factor which selection of therapy for a
hepatitis B positive patient should be based upon?
A. Efficacy
B. Potential of resistance
C. Toxicity
D. Patient and provider preference
E. All of the Above
4. In a study by Rosen et al. of adult prisoners entering the North
Carolina Department of Corrections, the authors estimate that between
23% and 67% of HIV cases remained undetected.
TRUE or FALSE
5. Which of the following medications approved for the treatment of
hepatitis B virus should NOT be taken by patients with severe depression
or unstable psychiatric disorders?
A. Lamivudine
B. Entecavir
C. Interferon
D. Both A and C
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COURSE EVALUATION - MEC #7256
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation
Faculty
Content
How well did this activity avoid com-
mercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate
this activity?
Excellent Very Good Good Fair Poor
II. Course Objectives
Were the following overall course objectives met? At the conclusion of this presentation, are you able to:
III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.
b. Additional Comments
YES NO SOMEWHAT
YES NO SOMEWHAT
YES NO SOMEWHAT
The learner will be able to describe the recommended treatment, dosing, and monitoring options for
the treatment and management of the hepatitis B virus.
The learner will be able to explain the prevention, screening, and diagnosis measures for the
hepatitis B virus.
The learner will be able to discuss the most significant studies presented at the 2008 Conference on
Retroviruses and Opportunistic Infections (CROI).
2008 National STD Prevention Conference
Chicago, IL
March 10-13, 2008
Visit: http://www.cdc.gov/stdconference/default.htm
Infectious Diseases: Adult Issues in the Outpatient
and Inpatient Settings
Sarasota, FL
March 10-14, 2008
Visit: http://www.ams4cme.com
Strengthening Connections between Parents and Children
Affected by Substance Abuse, HIV and Incarceration
San Francisco, CA
March 12-14, 2008
Visit: http://aia.berkeley.edu/strengthening_connections/index.html
HIV Testing of Defendants of Felony Sexual Assault
March 13, 2008
Satellite Conference, NY State
Visit: http://www.nyhealth.gov/diseases/aids/training/broadcast/index.htm
International Conference on Emerging Infectious Diseases
Atlanta, GA
March 16-19, 2008
Visit: http://www.iceid.org/
2nd Annual Academic and Health Policy Conference on
Correctional Health
Boston Marriott, Quincy, MA
March 27-28, 2008
Visit: http://www.umassmed.edu/Correctional_Health_Conf/index.aspx
Rapid HIV Testing & Diagnosing Acute HIV Infection
Satellite Videoconference & Webcast
April 18, 2008
12:30-2:30 p.m. (ET)
CME's & Nursing credits, No Fees
Visit: www.amc.edu/hivconference
(518) 262-4674
ybarraj@mail.amc.edu
16th Texas HIV/STD Conference
May 15-22, 2008
Austin, TX
Visit: http://www.dshs.state.tx.us/hivstd/conference/2008/default.shtm
Updates in Correctional Health Care
San Antonio, TX
May 17-20, 2008
Viist: http://www.ncchc.org/education/index.html
HIV/AIDS 2008:
The 20th Annual National Conference on Social Work and
HIV/AIDS
Washington D.C.
March 22-25, 2008
Visit: http://socialwork.bc.edu/outreach/hiv-aids
2008 HIV Prevention Leadership Summit
Detroit, MI
June 11-14, 2007
Visit: http://nmac.org/conferences___trainings/HPLS/
SAVE THE DATES
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